Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production.

Authors: Deshmukh, Hitesh S; Shaver, Colleen; Case, Lisa M; Dietsch, Maggie; Wesselkamper, Scott C; Hardie, William D; Korfhagen, Thomas R; Corradi, Massimo; Nadel, Jay A; Borchers, Michael T; Leikauf, George D

Published In Am J Respir Cell Mol Biol, (2008 Apr)

Abstract: Chronic obstructive pulmonary disease (COPD), a global public health problem, is characterized by progressive difficulty in breathing, with increased mucin production, especially in the small airways. Acrolein, a constituent of cigarette smoke and an endogenous mediator of oxidative stress, increases airway mucin 5, subtypes A and C (MUC5AC) production; however, the mechanism remains unclear. In this study, increased mMUC5AC transcripts and protein were associated with increased lung matrix metalloproteinase 9 (mMMP9) transcripts, protein, and activity in acrolein-exposed mice. Increased mMUC5AC transcripts and mucin protein were diminished in gene-targeted Mmp9 mice [Mmp9((-/-))] or in mice treated with an epidermal growth factor receptor (EGFR) inhibitor, erlotinib. Acrolein also decreased mTissue inhibitor of metalloproteinase protein 3 (an MMP9 inhibitor) transcript levels. In a cell-free system, acrolein increased pro-hMMP9 cleavage and activity in concentrations (100-300 nM) found in sputum from subjects with COPD. Acrolein increased hMMP9 transcripts in human airway cells, which was inhibited by an MMP inhibitor, EGFR-neutralizing antibody, or a mitogen-activated protein kinase (MAPK) 3/2 inhibitor. Together these findings indicate that acrolein can initiate cleavage of pro-hMMP9 and EGFR/MAPK signaling that leads to additional MMP9 formation. Augmentation of hMMP9 activity, in turn, could contribute to persistent excessive mucin production.

PubMed ID: 18006877 Exiting the NIEHS site

MeSH Terms: Acrolein/pharmacology*; Animals; Enzyme Activation/drug effects; Gene Expression Regulation, Enzymologic/drug effects; Humans; Lung/drug effects; Lung/enzymology; Lung/pathology; MAP Kinase Signaling System/drug effects; Male; Matrix Metalloproteinase 9/genetics; Matrix Metalloproteinase 9/metabolism*; Mice; Mitogen-Activated Protein Kinase 1/metabolism; Mitogen-Activated Protein Kinase 3/metabolism; Mucin 5AC; Mucins/biosynthesis*; Mucins/genetics; Mucins/metabolism; Pulmonary Disease, Chronic Obstructive/enzymology; Pulmonary Disease, Chronic Obstructive/pathology; RNA, Messenger/genetics; RNA, Messenger/metabolism; Receptor, Epidermal Growth Factor/metabolism; Sputum/drug effects; Sputum/enzymology; Tissue Inhibitor of Metalloproteinase-3/genetics; Tissue Inhibitor of Metalloproteinase-3/metabolism

to Top